| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 19, 2011For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can pass illnesses back and forth. The Centers for Disease Control and Prevention estimates that children have about two to nine illnesses per year, nearly double the number of colds adolescents and adults experience during the same timeframe.
19 Apr 2011 For parents, trying to determine whether to take a child who is experiencing the signs of a cold to the doctor can be a regular occurrence. From runny noses to ear infections, kids can...
-
Apr 15, 2011CSL Behring, a world leader in the development of plasma-derived and recombinant therapeutics, today announced the winners of this year’s prestigious CSL Behring Prof. Heimburger Award 2011. The announcement coincides with World Hemophilia Day and reflects this year’s theme to "Be Inspired, Get Involved in Treatment for All.
15 Apr 2011 CSL Behring, a world leader in the development of plasma-derived and recombinant therapeutics, today announced the winners of this year’s prestigious CSL Behring – Prof. Heimburger...
-
Mar 21, 2011Data presented by CSL Behring today suggest that treatment with higher dose Hizentra (IgPro 20) correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies (PI). These data, presented at the 2011 American Academy of Allergy, Asthma and Immunology annual meeting, derived from two recent trials of Hizentra, one performed in the United States and one in the European Union, and aimed to show the relationship between subcutaneous IgG (SCIg) dosage and clinical outcomes.
21 Mar 2011 Data presented by CSL Behring today suggest that treatment with higher dose Hizentra® (IgPro 20) correlates with reduced risk of infection and missed school or work among patients...
-
Mar 19, 2011CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC) immunoglobulin G (IgG) following administration to be simulated with a high degree of accuracy and precision.
19 Mar 2011 CSL Behring today announced the development of an innovative pharmacokinetic (PK) model that allows the absorption, distribution, metabolism, and elimination of subcutaneous (SC)...
-
Mar 2, 2011These awards honor accountable companies for openly sharing high quality information about therapies.
02 Mar 2011 CSL Behring was recognized in the 2010 Prescrire Information Awards. These awards honor accountable companies for openly sharing high quality information about therapies. Results were...